Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chimerix

8.54
+0.0000
Volume:- -
Turnover:- -
Market Cap:801.08M
PE:-8.63
High:8.54
Open:8.54
Low:8.54
Close:8.54
Loading ...

Chimerix price target raised to $7 from $5 at JonesResearch

TIPRANKS
·
11 Dec 2024

Dow Falls 150 Points; Oracle Posts Downbeat Results

Benzinga
·
10 Dec 2024

Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?

Benzinga
·
10 Dec 2024

Investors Look Ahead to Key Inflation Data as US Futures Tread Water in Tuesday's Premarket

MT Newswires Live
·
10 Dec 2024

Chimerix Shares Double Premarket on Potential for Dordaviprone Approval in Q3 Following 'Extensive' Discussions With FDA

MT Newswires Live
·
10 Dec 2024

24H | Chimerix Shares Soar 173% as Company Plans FDA Submission of Cancer Drug Dordaviprone

Dow Jones
·
10 Dec 2024

BUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug

Reuters
·
10 Dec 2024

Chimerix to submit dordaviprone NDA to FDA, seeks accelerated approval

TIPRANKS
·
10 Dec 2024

BRIEF-Chimerix To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27m-Mutant Diffuse Glioma Before Year-End

Reuters
·
10 Dec 2024

Chimerix Inc - Potential Approval for Dordaviprone in Q3 2025

THOMSON REUTERS
·
10 Dec 2024

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients With Recurrent H3 K27m-Mutant Diffuse Glioma Before Year-End

THOMSON REUTERS
·
10 Dec 2024

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

GlobeNewswire
·
10 Dec 2024

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
07 Dec 2024

Chimerix Price Target Maintained With a $6.00/Share by Wedbush

Dow Jones
·
19 Nov 2024

Chimerix’s Phase 2 Reassessment Boosts Buy Rating Amid Promising Data and Strong Financials

TIPRANKS
·
12 Nov 2024

Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Chimerix’s Dordaviprone Shows Promising Efficacy in H3 K27M-mutant Diffuse Glioma with $11 Price Target

TIPRANKS
·
11 Nov 2024

Press Release: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting

Dow Jones
·
11 Nov 2024

Chimerix Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
09 Nov 2024

Q3 2024 Chimerix Inc Earnings Call

Thomson Reuters StreetEvents
·
08 Nov 2024